OCM
AKBA icon

Orchard Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Orchard Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-53,510
Closed -$74.4K – 45
2026
Q1 		$74.4K Hold
53,510
– – 0.08% 45
2025
Q4 		$86.2K Hold
53,510
– – 0.07% 43
2025
Q3 		$146K Hold
53,510
– – 0.13% 43
2025
Q2 		$195K Hold
53,510
– – 0.22% 36
2025
Q1 		$103K Sell
53,510
-7,200
-12% -$14.7K 0.07% 38
2024
Q4 		$115K Sell
60,710
-24,006
-28% -$41.7K 0.05% 55
2024
Q3 		$112K Sell
84,716
-2,110
-2% -$2.82K 0.04% 55
2024
Q2 		$88.6K Sell
86,826
-21,634
-20% -$26.7K 0.03% 42
2024
Q1 		$198K Buy
108,460
+21,634
+25% +$34.6K 0.06% 47
2023
Q4 		$108K Buy
86,826
+20,000
+30% +$20.4K 0.03% 44
2023
Q3 		$76.2K Hold
66,826
– – 0.03% 42
2023
Q2 		$61.1K Hold
66,826
– – 0.02% 46
2023
Q1 		$37.4K Hold
66,826
– – 0.01% 48
2022
Q4 		$38.6K Sell
66,826
-185,000
-73% -$58K 0.01% 50
2022
Q3 		$80K Hold
251,826
– – 0.03% 46
2022
Q2 		$89K Sell
251,826
-1,510,905
-86% -$634K 0.03% 47
2022
Q1 		$1.26M Buy
1,762,731
+169,200
+11% +$362K 0.36% 36
2021
Q4 		$3.6M Hold
1,593,531
– – 1.06% 29
2021
Q3 		$4.59M Hold
1,593,531
– – 1.38% 29
2021
Q2 		$6.04M Buy
1,593,531
+53,277
+3% +$179K 1.74% 27
2021
Q1 		$5.21M Buy
1,540,254
+683,116
+80% +$2.46M 1.64% 29
2020
Q4 		$2.4M Buy
+857,138
New +$2.5M 1.02% 32

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Orchard Capital Management's AKBA Position: Q2 2026 in Review

Orchard Capital Management sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 53,510 shares — an estimated $74.4K sold.

Orchard Capital Management first reported a position in AKBA in Q4 2020 and held it in 22 quarters. The position peaked at $6.04M in Q2 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Orchard Capital Management reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Orchard Capital Management sold 53,510 Akebia Therapeutics shares in Q2 2026, an estimated $74.4K.
  • Orchard Capital Management first reported a position in Akebia Therapeutics in Q4 2020 and held it in 22 quarters.
  • Orchard Capital Management's Akebia Therapeutics position peaked at $6.04M in Q2 2021.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Orchard Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.